Patents by Inventor Carola Tilgmann

Carola Tilgmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the prevention of thromboembolic disorders
    Patent number: 8329693
    Abstract: A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: December 11, 2012
    Assignee: Orion Corporation
    Inventors: Heimo Haikala, Jouko Levijoki, Piero Pollesello, Carola Tilgmann
  • METHOD FOR THE PREVENTION OF THROMBOEMBOLIC DISORDERS
    Publication number: 20110301166
    Abstract: A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.
    Type: Application
    Filed: August 11, 2011
    Publication date: December 8, 2011
    Inventors: Heimo Haikala, Jouko Levijoki, Piero Pollesello, Carola Tilgmann
  • Method for the prevention of thromboembolic disorders
    Patent number: 8017609
    Abstract: A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: September 13, 2011
    Assignee: Orion Corporation
    Inventors: Heimo Haikala, Jouko Levijoki, Piero Pollesello, Carola Tilgmann
  • Method For The Prevention Of Thromboembolic Disorders
    Publication number: 20080039467
    Abstract: A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.
    Type: Application
    Filed: May 12, 2005
    Publication date: February 14, 2008
    Inventors: Heimo Haikala, Jouko Levijoki, Piero Pollesello, Carola Tilgmann
  • Compounds for deactivating phospholamban function on Ca-ATPase (phospholamban inhibitors)
    Patent number: 6774103
    Abstract: This invention relates to determining the three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. The invention also relates to methods for rational drug design enabling the design of phospholamban inhibitors based on using the three-dimensional structure data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms. The invention also relates to phospholamban inhibiting compounds with certain structural, physicochemical and spatial characteristics that allow for the interaction of said compounds with specific residues of the active site of phospholamban.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 10, 2004
    Assignee: Orion Corporation
    Inventors: Piero Pollesello, Martti Ovaska, Jukka Tenhunen, Jukka Vidgren, Marjo Yliperttula-Ikonen, Carola Tilgmann, Timo Lotta, Juha Kaivola
  • Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)
    Patent number: 6538022
    Abstract: This invention relates to determining the three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. The invention also relates to methods for rational drug design enabling the design of phospholamban inhibitors based on using the three-dimensional structure data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms. The invention also relates to phospholamban inhibiting compounds with certain structural, phsicochemical and spatial characteristics that allow for the interaction of said compounds with specific residues of phospholamban.
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: March 25, 2003
    Assignee: Orion Corporation
    Inventors: Piero Pollesello, Martti Ovaska, Jukka Tenhunen, Jukka Vidgren, Marjo Yliperttula-Ikonen, Carola Tilgmann, Timo Lotta, Juha Kaivola
  • Phospholamban inhibitors and a method for increasing coronary flow
    Patent number: 6265421
    Abstract: A method for obtaining direct dilatation of the coronary arteries by administering a therapeutically effective amount of a phospholamban inhibitor is described. Compounds which are effective in relieving the inhibitory effects of phospholamban on cardiac sarcoplasmic reticulum Ca2+-ATPase are also described.
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: July 24, 2001
    Assignee: Orion Corporation
    Inventors: Jarmo Pystynen, Heimo Haikala, Petri Kaheinen, Juha Kaivola, Piero Pollesello, Ismo Ulmanen, Jukka Tenhunen, Carola Tilgmann, Eija Tiainen, Kari Lönnberg, Pentti Nore, Seppo Parhi, Arto Karjalainen, Jouko Levijoki